Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNantes University Hospital
About this trial
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.
Eligibility criteria
Qualifiers
Patient with CLL candidates ou exposed to BTKd
Patient who has provided informed consent to participate in the study.
Patient covered by a social security health insurance plan
Disqualifiers
Minor patients.
Adults under guardianship.
Protected persons.
Trial design
Treatments tested in this trial
- Non-Interventional Sample Collection and Analysis
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov